Management of Intracerebral Hemorrhage: Update and Future Therapies

Curr Neurol Neurosci Rep. 2021 Oct 2;21(10):57. doi: 10.1007/s11910-021-01144-9.

Abstract

Purpose of review: Intracerebral hemorrhage (ICH) represents about 15% of all strokes in the USA, but almost 50% of fatal strokes. There are many causes of ICH, but the most common are hypertension and cerebral amyloid angiopathy. This review will discuss new advances in the treatment of intracerebral hemorrhage.

Recent findings: The treatment of ICH focuses on management of edema, aggressive blood pressure reduction, and correction of coagulopathy. Early initiation of supportive medical therapies, including blood pressure management, in a neurological intensive care unit reduces mortality, but at present there is no definitive, curative therapy analogous to mechanical thrombectomy for ischemic stroke. Nonetheless, new medical and surgical approaches promise more successful management of ICH patients, especially new approaches to surgical management. In this review, we focus on the current standard of care of acute ICH and discuss emerging therapies that may alter the landscape of this devastating disease.

Keywords: Cerebral amyloid angiopathy; Cerebral hemorrhage; External ventricular drain; Intracerebral hemorrhage; Microhemorrhage.

Publication types

  • Review

MeSH terms

  • Blood Pressure
  • Cerebral Amyloid Angiopathy* / complications
  • Cerebral Amyloid Angiopathy* / therapy
  • Cerebral Hemorrhage / therapy
  • Humans
  • Hypertension* / therapy
  • Intensive Care Units